This program is designed to exploit very recent advances in genetic engineering, cell biology, and a humanized animal model to develop cell- based immunotherapy for clinical use in HIV infected patients. The scientific resources of three laboratories that have previously successfully collaborated will be coordinated to achieve this goal. Accumulating data support the importance of cytotoxic T-lymphocytes (CTLs) in the host response to HIV, the etiologic agent of AIDS. Project I aims to create populations of functional CTLs against HIV that may be given to patients without MHC restriction, e.g., """"""""universal donor"""""""" effector cells. The chimeric antigenic recognition elements of these universal donor cells will be constructed utilizing reagents and insights derived from Project II. This second project aims to identify important effector elements by studying cloned CTLs and human monoclonal antibodies derived from HIV infected patients. The in vitro effector properties of universal donor chimeric CTLs will be assessed in Project II as well. The in vivo activities of primary and universal donor CTLs in HIV infected humanized SCID mice will be studied in Project III. Parallel work using these approaches in the CMV infection model will be pursued to analyze similarities and differences with HIV. This strategy provides the opportunity to create genetically altered immune effector cells that could be clinically provided to patients with HIV independent of the usual transplantation barriers, thereby improving host immune function.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI031686-02
Application #
3547852
Study Section
Special Emphasis Panel (SRC (41))
Project Start
1991-09-30
Project End
1994-08-31
Budget Start
1992-09-01
Budget End
1993-08-31
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Yamaguchi, K; Byrn, R A (1995) Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim Biophys Acta 1253:136-40
Zhang, D; Zhang, N; Wick, M M et al. (1995) HIV type 1 protease activation of NF-kappa B within T lymphoid cells. AIDS Res Hum Retroviruses 11:223-30
Mosier, D; Sieburg, H (1994) Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 15:332-9
Yamaguchi, K; Groopman, J E; Byrn, R A (1994) The regulation of HIV by retinoic acid correlates with cellular expression of the retinoic acid receptors. AIDS 8:1675-82
Yamaguchi, K; Zhang, D; Byrn, R A (1994) A modified nonradioactive method for northern blot analysis. Anal Biochem 218:343-6
Chamow, S M; Zhang, D Z; Tan, X Y et al. (1994) A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J Immunol 153:4268-80
Papp, B; Zhang, D; Groopman, J E et al. (1994) Stimulation of human immunodeficiency virus type 1 expression by ceramide. AIDS Res Hum Retroviruses 10:775-80
Yamaguchi, K; Zhang, D; Byrn, R A (1994) Fluorescent primers allow direct confirmation of restriction enzyme cleavage of PCR products. Biotechniques 17:649-50, 652
Roberts, M R; Qin, L; Zhang, D et al. (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84:2878-89